Newborn screening (NBS) programs have become a cornerstone for the early detection of CAH, primarily through the measurement of 17-hydroxyprogesterone (17-OHP), a precursor metabolite that accumulates due to CYP21A2 enzyme deficiency. Here, CYP21A2 is linked to congenital adrenal hyperplasia.